Arrowhead Pharmaceuticals Inc. (ARWR) Reports Q3 Loss of $0.96
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $60.63 +1.85%
Financial Fact:
NET INCOME (LOSS) ATTRIBUTABLE TO ARROWHEAD: -19.42M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
NET INCOME (LOSS) ATTRIBUTABLE TO ARROWHEAD: -19.42M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q3 EPS of ($0.96), versus ($0.68) reported last year. Revenue for the quarter came in at $15.8 million, versus $32.4 million reported last year.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CPS Technologies (CPSH) Reports In-Line Q3 EPS
- Datadog stock tumbles 19% despite earnings beat
- Grainger (GWW) Tops Q3 EPS by 87c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
